• Explore /
  • Poster
  • / Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma.

Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma.

Abstract Poster

Authors

null

Patrick Y. Wen

Dana-Farber Cancer Institute, Boston, MA

Patrick Y. Wen , Ingo K. Mellinghoff , Shakti Ramkissoon , Brian Michael Alexander , Mikael L. Rinne , Howard Colman , Antonio Marcilio Padula Omuro , Lisa Marie DeAngelis , Mark R. Gilbert , John Frederick De Groot , Timothy Francis Cloughesy , Andrew S. Chi , Eudocia Quant Lee , Lakshmi Nayak , Tracy Batchelor , Susan Marina Chang , Michael Prados , David A. Reardon , Keith L. Ligon , W. K. Alfred Yung

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 2019)

DOI

10.1200/jco.2014.32.15_suppl.2019

Abstract #

2019

Poster Bd #

9

Abstract Disclosures

Similar Posters

First Author: Patrick Y. Wen

First Author: David A. Reardon

First Author: Kent C. Shih

First Author: Rana R. McKay